Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

Last week, it was announced that Genentech, a founding company in the biotech industry, plans to build a $700 million, ...

The Mumbai-based firm expects a quick recovery in FY27, and is on track to achieve its target of becoming a $2-billion ...

Qiagen has a relatively well-diversified portfolio across four segments. Find out my recommendation on QGEN stock here.

Texas governor Greg Abbott announced that NtxBio, a Rio Rancho, New Mexico healthcare biomanufacturing company, is building a ...

Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA ...

By Ludwig Burger FRANKFURT (Reuters) -German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more ...

Marking the next milestone in their robust growth story, Thane-based Ekavta Group has shared their impressive topline ...

Some of it is in the new Boston home of Eli Lilly & Co ., a $700 million research and development facility along Fort Point ...

Amidst policy shifts and layoffs at the FDA, some biotechs are considering moving early clinical trials to Europe or ...

A very different kind of “hog farm” being built by United Therapeutics Corp. on the edge of Stewartville to raise gene-edited ...